Literature DB >> 26501073

JAK-STAT in lymphoproliferative disorders.

Raul Rabadan1, Giorgio Inghirami1.   

Abstract

Entities:  

Keywords:  STAT3 signaling; T-cell lymphoma; lymphomageneis; mutations

Year:  2015        PMID： 26501073      PMCID： PMC4606001          DOI： 10.18632/oncoscience.189

Source DB:  PubMed          Journal:  Oncoscience        ISSN： 2331-4737


× No keyword cloud information.
  8 in total

1.  Convergent mutations and kinase fusions lead to oncogenic STAT3 activation in anaplastic large cell lymphoma.

Authors:  Ramona Crescenzo; Francesco Abate; Elena Lasorsa; Fabrizio Tabbo'; Marcello Gaudiano; Nicoletta Chiesa; Filomena Di Giacomo; Elisa Spaccarotella; Luigi Barbarossa; Elisabetta Ercole; Maria Todaro; Michela Boi; Andrea Acquaviva; Elisa Ficarra; Domenico Novero; Andrea Rinaldi; Thomas Tousseyn; Andreas Rosenwald; Lukas Kenner; Lorenzo Cerroni; Alexander Tzankov; Maurilio Ponzoni; Marco Paulli; Dennis Weisenburger; Wing C Chan; Javeed Iqbal; Miguel A Piris; Alberto Zamo'; Carmela Ciardullo; Davide Rossi; Gianluca Gaidano; Stefano Pileri; Enrico Tiacci; Brunangelo Falini; Leonard D Shultz; Laurence Mevellec; Jorge E Vialard; Roberto Piva; Francesco Bertoni; Raul Rabadan; Giorgio Inghirami
Journal:  Cancer Cell       Date:  2015-04-13       Impact factor: 31.743

Review 2.  Revisiting STAT3 signalling in cancer: new and unexpected biological functions.

Authors:  Hua Yu; Heehyoung Lee; Andreas Herrmann; Ralf Buettner; Richard Jove
Journal:  Nat Rev Cancer       Date:  2014-11       Impact factor: 60.716

Review 3.  The future of JAK inhibition in myelofibrosis and beyond.

Authors:  John O Mascarenhas; Nicholas C P Cross; Ruben A Mesa
Journal:  Blood Rev       Date:  2014-06-28       Impact factor: 8.250

Review 4.  Anaplastic lymphoma kinase in human cancer.

Authors:  Antonella Barreca; Elena Lasorsa; Ludovica Riera; Rodolfo Machiorlatti; Roberto Piva; Maurilio Ponzoni; Ivo Kwee; Francesco Bertoni; Pier Paolo Piccaluga; Stefano A Pileri; Giorgio Inghirami
Journal:  J Mol Endocrinol       Date:  2011-07-04       Impact factor: 5.098

Review 5.  Targeting JAK kinase in solid tumors: emerging opportunities and challenges.

Authors:  M Buchert; C J Burns; M Ernst
Journal:  Oncogene       Date:  2015-05-18       Impact factor: 9.867

Review 6.  The JAK-STAT pathway at twenty.

Authors:  George R Stark; James E Darnell
Journal:  Immunity       Date:  2012-04-20       Impact factor: 31.745

7.  Stat3 is required for ALK-mediated lymphomagenesis and provides a possible therapeutic target.

Authors:  Roberto Chiarle; William J Simmons; Honjying Cai; Girish Dhall; Alberto Zamo; Regina Raz; James G Karras; David E Levy; Giorgio Inghirami
Journal:  Nat Med       Date:  2005-05-15       Impact factor: 53.440

Review 8.  Deregulated JAK/STAT signalling in lymphomagenesis, and its implications for the development of new targeted therapies.

Authors:  Linda M Scott; Maher K Gandhi
Journal:  Blood Rev       Date:  2015-06-11       Impact factor: 8.250
  8 in total
  1 in total

1.  REG3A promotes the proliferation, migration, and invasion of gastric cancer cells.

Authors:  Zhou-Feng Chen; Zhi-Ming Huang; Hai-Bo Xue; Xiu-Qing Lin; Ren-Ping Chen; Meng-Jun Chen; Rui-Fang Jin
Journal:  Onco Targets Ther       Date:  2017-04-06       Impact factor: 4.147
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.